MSLE · Satellos Bioscience Inc. · Investor Relations

Satellos Bioscience Inc. (Nasdaq: MSLE , TSX: MSCL ) (“Satellos” or the “Company”), a clinical-stage biotechnology company focused on restoring natural muscle repair and regeneration in degenerative muscle diseases, today announced that management will participate in a fireside chat at the Guggenheim Securities Emerging Outlook: Biotech Summit 2026 in NYC on Thursday, Feb. 12, 2026, at 10 a.m. ET. The fireside chat will be available via live webcast on the Events and Presentations page in the Investors section of the Company’s website. A replay will be available following the event. Members of the Satellos leadership team will also be available for one-on-one investor meetings during the conference. Investors interested in scheduling a meeting may contact their Guggenheim representative or reach out directly to Satellos at ir@satellos.com . ABOUT SATELLOS BIOSCIENCE INC. Satellos is a clinical-stage drug development company focused on restoring natural muscle repair and regeneration

Satellos Bioscience Inc . (Nasdaq: MSLE, TSX: MSCL) (“Satellos” or the “Company”), a clinical-stage biotechnology company developing life-improving medicines to treat degenerative muscle diseases, today announced that it has completed its previously-announced underwritten public offering (the “Offering”) of 5,168,019 common shares, which includes the exercise of the underwriters’ option to purchase an additional 712,574 common shares and, in lieu of common shares for certain investors, pre-funded warrants to purchase 495,049 common shares. The common shares were sold at a price of US$10.10 per share (C$13.81 per common share) and the pre-funded warrants were sold at a price of US$10.09999 per pre-funded warrant (C$13.80999 per pre-funded warrant), which represents the per share price for the common shares less the C$0.00001 per share exercise price for each pre-funded warrant. The total gross proceeds to the Company were approximately US$57.2 million, before deducting the underwriting

BASE SHELF PROSPECTUS IS ACCESSIBLE, AND PROSPECTUS SUPPLEMENT WILL BE ACCESSIBLE WITHIN TWO BUSINESS DAYS ON SEDAR+ Satellos Bioscience Inc . (TSX: MSCL, Nasdaq: MSLE) (“Satellos” or the “Company”), a clinical-stage biotechnology company developing life-improving medicines to treat degenerative muscle diseases, today announced the pricing of its previously announced public offering (the “Offering”) of 4,455,445 common shares and, in lieu of common shares for certain investors, pre-funded warrants to purchase 495,049 common shares. The common shares are being sold at a price of US$10.10 per share (C$13.81 per common share) and the pre-funded warrants are being sold at a price of US$10.09999 per pre-funded warrant (C$13.80999 per pre-funded warrant), which represents the per share price for the common share less the C$0.00001 per share exercise price for each pre-funded warrant. The pre-funded warrants do not expire. In addition, the Company has granted the underwriters a 30-day option